Screener
BioCryst Pharmaceuticals BCRX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
FAQ
- What is BioCryst Pharmaceuticals's total equity?
- BioCryst Pharmaceuticals (BCRX) reported total equity of -$454.29M in Q2 2026.
- How has BioCryst Pharmaceuticals's total equity changed year-over-year?
- BioCryst Pharmaceuticals's total equity decreased by 7.8% year-over-year, from -$421.59M to -$454.29M.
- What is the long-term trend for BioCryst Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's total equity has grown at a 44.0% compound annual growth rate (CAGR), from -$19.26M to -$119.15M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about BioCryst Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude